Several papers on the effect of psychosocial factors on adolescent alcohol use have been published over the past several years. Undoubtedly, psychosocial influences play an important part in alcohol use. However, biological factors and their interaction with environmental factors also play an important role in the development of alcohol use disorders in adolescents.
Alcohol misuse tends to run in families, and it is estimated that 40% to 60% of the variance of risk is explained by genetic influences (1, 2) . Numerous welldesigned twin and adoption studies have demonstrated that genetic factors are important in determining vulnerability to alcoholism (3) (4) (5) . Children of patients with alcohol dependence are 5 times more likely to develop alcohol-related problems than are children of nonalcoholdependent individuals (6, 7) . There is a tendency for people who misuse alcohol to marry individuals who also abuse alcohol (assortative mating) (8) . Thus, many adolescent alcohol misusers are from families with a high proportion of alcohol abuse or dependence. Some of these adolescents were exposed to alcohol in utero. Familial loading for alcohol dependence is a risk factor for developing psychiatric and neurological disorders in children and adolescents (9, 10) . A recent study suggests that offspring from families with a high proportion of alcoholism differ in both neuroanatomical and neurophysiological characteristics. These differences could not be explained by a personal history of alcohol consumption or by specific childhood or adolescent psychopathology (10) . Ethanol use during adolescence may disrupt maturational processes in certain brain regions (11) . Dopamine projection regions, for example, are undergoing developmental change during adolescence (11) . The importance of dopaminergic mechanisms in the biology of alcohol-induced award is well known (12) (13) (14) . Withdrawal from alcohol is associated with decreased firing of dopaminergic neurons in the ventral tegmental area and decreased dopamine release in the nucleus accumbens (15) .
In summary, genetic, developmental, and acquired biological factors affect adolescent alcohol use. Many adolescent drinkers have subtle or overt developmental deficits or psychiatric disorders that require appropriate treatments. Further studies of the role of biological factors in initiation and continuation of adolescent alcohol use are necessary.
Minor Strokes Related to Paroxetine Discontinuation in an Elderly Subject: Emergent Adverse Events
Dear Editor:
Abrupt interruption of extended treatment with selective serotonin reuptake inhibitors (SSRIs) may lead to the emergence of discontinuation syndrome. SSRI discontinuation syndrome may manifest with diverse psychological and physical symptoms, including dizziness, shock-like sensory symptoms, anxiety, irritability, agitation, insomnia, and depression (1). Stroke-like neurological symptoms have been reported in 2 patients who developed severe SSRIinduced discontinuation syndrome (2) . However, this is the first report that illustrates an elderly man with cerebrovascular disease developing minor strokes following abrupt discontinuation of long-term paroxetine treatment.
Case Report
Mr A, aged 67 years, had chronic depression. He was investigated for dementia secondary to cerebrovascular disease because he developed memory deficits in the background of type 2 diabetes mellitus, hypertension, and coronary artery disease. He was diagnosed with recurrent major depression over 10 years ago and remained normothymic on long-term maintenance treatment with paroxetine 40 mg daily. Review of his history suggested that he had developed minor strokes involving vertebrobasilar artery territory on 2 occasions following abrupt discontinuation of paroxetine. On the first occasion, 24 to 48 hours after accidentally stopping paroxetine treatment, he became anxious, agitated, irritable, confused, showing severe gait ataxia and bilateral motor weakness. He was admitted to a tertiary care hospital and investigated for vertebrobasilar insufficiency. Magnetic resonance imaging (MRI) showed extensive hyperintense T2 signal foci within cerebral white matter, as well as in the left pons, suggesting nonspecific smallvessel ischemic disease. Magnetic resonance angiography revealed mild occlusion or hypoplasia of the right A1 segment of the anterior cerebral artery.
His blood pressure was elevated to 150/100 mm Hg. The symptoms of agitation, anxiety, insomnia, gait ataxia, and bilateral motor weakness were cleared 24 to 48 hours after paroxetine treatment was reinstituted at the previous dosage. Four months later, his cardiologist abruptly discontinued paroxetine treatment, owing to potential anticholinergic and cardiac side effects. The patient was readmitted to the same tertiary hospital with anxiety, agitation, confusion, gait ataxia, and bilateral motor weakness. A repeat MRI showed no progression in cortical white matter and pontine ischemic changes. The discontinuation symptoms, ataxia, and motor weakness resolved within 48 hours after the reintroduction of paroxetine treatment at the previous dosage. Because vertebrobasilar insufficiency lasted for more than 24 hours and brain parenchyma might be irreversibly altered owing to prolonged ischemic attack, the diagnosis of ministroke involving vertebrobasilar territory was considered.
Discussion
The emergence of anxiety, agitation, and insomnia within 24 to 48 hours of abrupt discontinuation of paroxetine maintenance treatment and the resolution of these symptoms after reinstating the previous paroxetine treatment concurs with the diagnosis of SSRI discontinuation syndrome (1). This patient suffered minor strokes involving vertebrobasilar territory, as determined by neurological investigations and stroke neurologists. Hence, in this patient manifested ataxia and motor weakness during a discontinuation phase may indicate minor stroke involving vertebrobasilar territory, rather than the physical symptoms of discontinuation syndrome. Moreover, in the presence of cerebrovascular disease, ataxia and motor weakness could not be considered as discontinuation symptoms. Further, since there was a temporal relation between the onset of minor strokes and the discontinuation of paroxetine treatment on both occasions, it is unlikely that these minor strokes were just coincidental manifestations of the underlying cerebrovascular disease. The possibilities of SSRI treatmentassociated cerebrovascular bleeding and vasoconstrictive stroke may be irrelevant: this patient developed minor strokes after the discontinuation of paroxetine maintenance treatment (3, 4) .
Paroxetine has been frequently implicated in SSRI discontinuation syndrome, owing to its short half-life (5) . Cholinergic overdrive activating monoaminergic systems, coupled with hyposerotonergic state after the discontinuation of paroxetine treatment, may be responsible for discontinuation symptoms (6, 7) . Elevated blood pressure and a possible decrease in cerebrovascular reserve because of activation of catecholamines and resulting anxiety during discontinuation syndrome might have contributed to minor strokes in this patient (8, 9) . Given the possibility of cerebrovascular events as consequences to anxiety and agitation during discontinuation syndrome, it is imperative to minimize discontinuation symptoms by slowly tapering SSRI treatment in elderly subjects with cerebrovascular disease.
